Stühler, Viktoria
Herrmann, Lisa
Rausch, Steffen
Stenzl, Arnulf
Bedke, Jens
Funding for this research was provided by:
Universitätsklinikum Tübingen
Article History
Received: 11 June 2022
Accepted: 25 June 2022
First Online: 30 July 2022
Declarations
:
: The authors declare no competing interests.
: Dr. Bedke has received institutional research funding from AstraZeneca, Astellas, BMS, Eisai, Ipsen, MSD, Novartis, Nektar, Pfizer, Roche, and Seattle Genetics; received honoraria from BMS and MSD on an institutional basis and from AstraZeneca, Astellas, BMS, Eisai, EUSA Pharma, Ipsen, MSD, Merck Serono, Novartis, Pfizer, and Roche on a personal basis.Dr. Stenzl: Consultancies and Speaker´s Bureau: Ipsen, Roche, Janssen, BMS, Alere, Stebabiotech, Synergo, Ferring, Astellas, Amgen, Sanofi Aventis, CureVac and study participation or research grants with institutional funding: Johnson & Johnson, Roche, Cepheid, Amgen, Bayer, CureVac, GemeDx biotechnologies GmbH, Novartis, Karl Storz, immatics biotechnologies GmbH.All other authors: declare no conflict of interest.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University of Tuebingen, Germany (078/2012/B02).